Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

laser light1 - abdominopelvic cavity1 - mortality risk1 - nephrolithiasis2 - acupuncture1 - journal of urology5 - intravenous injection1 - osteoporosis1 - jet1 - plos1 - xenical1 - vitamin k1 - obesity complications1 - positron emission tomography1 - clitoris3 - carboplatin1 - teen pregnancy1 - function of dialysis1 - sodium bicarbonate1 - biopsy outcome1 - birth weight1 - urodynamic testing6 - hyperpnea1 - hypoxia1 - psa tests1 - asco1 - nvasive follow-up tests1 - metastatic tumors1 - wake forest baptist medical center1 - gonococcal infection2 -